Stockscreener 앱 받기
1.84
3.37%
0.06
시간 외 거래:
1.84
전일 마감가:
$1.78
열려 있는:
$1.79
하루 거래량:
2.09M
Relative Volume:
0.98
시가총액:
$418.24M
수익:
-
순이익/손실:
$-179.82M
주가수익비율:
-1.3835
EPS:
-1.33
순현금흐름:
$-159.16M
1주 성능:
+8.24%
1개월 성능:
+35.29%
6개월 성능:
+97.85%
1년 성능:
+68.81%
1일 변동 폭
$1.72
$1.92
1주일 범위
$1.6701
$1.92
52주 변동 폭
$0.6617
$1.92
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
GOSS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.84 | 404.60M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
Why is Gossamer Bio Inc. stock attracting strong analyst attentionNavigate market shifts with confidence - jammulinksnews.com
Why Gossamer Bio Inc. stock attracts strong analyst attentionFree Join Group - Newser
Is Gossamer Bio Inc. a Top Dividend Stock to Watch in 2025Protected Capital Trading Plan - Newser
How strong is Gossamer Bio Inc. company’s balance sheetGet exclusive access to expert stock recommendations - jammulinksnews.com
What makes Gossamer Bio Inc. stock price move sharplyFree Stock Market Trend Analysis - Newser
What drives Gossamer Bio Inc. stock priceFree Investment Community - PrintWeekIndia
BlackRock, Inc. Expands Holdings in Gossamer Bio Inc. - GuruFocus
GOSS’s 2025 Market Dance: Up 86.05% – Time to Invest? - investchronicle.com
Is Gossamer Bio Inc. a good long term investmentConsistently superior profits - jammulinksnews.com
What analysts say about Gossamer Bio Inc. stockJaw-dropping returns - jammulinksnews.com
Gossamer Bio Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - jammulinksnews.com
How Gossamer Bio Inc. stock performs during market volatilityShort Term Risk Controlled Alerts - Newser
GOSS’s Stock Market Adventure: 30.77% YTD Growth Amidst Volatility - investchronicle.com
Gossamer Bio (NASDAQ:GOSS) Coverage Initiated by Analysts at Scotiabank - Defense World
Scotiabank Initiates Gossamer Bio at Sector Outperform With $11 Price Target - MarketScreener
Scotiabank Initiates Coverage of Gossamer Bio (GOSS) with Sector Outperform Recommendation - MSN
Gossamer Bio (NASDAQ:GOSS) Shares Down 3.2% – Time to Sell? - Defense World
Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell 3000 Growth Index - MarketScreener
Gossamer Bio, Inc.(NasdaqGS: GOSS) added to Russell Microcap Index - MarketScreener
Gossamer Bio Approves 2019 Incentive Award Plan - TipRanks
Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib - Insider Monkey
Gossamer Bio Announces Completion of Enrollment in Registrationa - GuruFocus
Gossamer Bio (GOSS) Wraps Up Enrollment for Phase 3 PAH Study | GOSS Stock News - GuruFocus
Gossamer Bio Announces Completion Of Enrollment In Registrational Phase 3 PROSERA Study For The Treatment Of PAH - MarketScreener
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH - The Joplin Globe
Gossamer Bio's Breakthrough PAH Drug Hits Major Milestone: 390 Patients Enrolled in Phase 3 Trial - Stock Titan
Squarepoint Ops LLC Has $65,000 Stake in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Brokers Offer Predictions for Gossamer Bio FY2026 Earnings - Defense World
Two Sigma Investments LP Raises Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) - Defense World
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rul - GuruFocus
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | GOSS Stock News - GuruFocus
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.22%
자본화:
|
볼륨(24시간):